Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.36 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 3/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | GNRHR | P30968 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CD38 | P28907 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL952788 | 0.90 | AR (0.41) | ARTAAR1PGRRXRARXRB | |
| SCHEMBL2031892 | 0.82 | MEN1 (0.40) | SLC6A2SLC6A4STIM1ORAI1AR | |
| SCHEMBL1008876 | 0.82 | TAAR1 (0.39) | TAAR1MEN1MAPTHPGDKMT2A | |
| SCHEMBL24146763 | 0.80 | AR (0.45) | ARPGR | |
| SCHEMBL12020324 | 0.80 | AR (0.42) | ARTAAR1HSD11B1MEN1HPGD | |
| SCHEMBL7103045 | 0.78 | KIF11 (0.38) | ARMEN1MAPTHPGDKMT2A | |
| SCHEMBL5407429 | 0.75 | SLC6A2 (0.43) | SLC6A2SLC6A4STIM1ORAI1TAAR1 | |
| SCHEMBL693177 | 0.75 | SLC6A2 (0.40) | SLC6A2SLC6A4STIM1ORAI1AR | |
| SCHEMBL2776951 | 0.75 | STIM1 (0.42) | SLC6A2SLC6A4STIM1ORAI1TAAR1 | |
| SCHEMBL14405515 | 0.75 | SLC6A2 (0.43) | SLC6A2SLC6A4STIM1ORAI1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149018-B2 | Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-19 | — | — | US | disclosed |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20200157073-A1 | SUBSTITUTED N-ARYLETHYL-2-AMINOQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-21 | — | — | US | disclosed |
| EP-3609869-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2020-02-19 | — | — | EP | disclosed |
| EP-3609870-A1 | SUBSTITUTED N-ARYLETHYL-2-AMINOQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2020-02-19 | — | — | EP | disclosed |
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
| CN-110730776-A | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and their use | 拜耳股份公司 | 2020-01-24 | — | — | CN | disclosed |
| CN-110709384-A | Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and their use | 拜耳股份公司 | 2020-01-17 | — | — | CN | disclosed |
| WO-2018189012-A1 | SUBSTITUTED N-ARYLETHYL-2-AMINOQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018189011-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2018-10-18 | — | — | WO | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| CN-101374516-A | Use of substituted 2-imidazole of imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| US-6528657-B2 | For use in electroluminescence light emission element and can emit lights of various colors when an energy such as electric energy or electromagnetic energy is applied thereto | TAIHO INDUSTRIES CO., LTD. (JP) | 2003-03-04 | — | — | US | disclosed |
| US-20030023099-A1 | Novel fluorescent carbazole derivative | HIROSE ENGINEERING CO., LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
| US-5686492-A | NMR DIAGNOSTIC AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, NAT1, EPX | SLC6A2 3264/4885SLC6A4 3468/4885STIM1 1855/4885 |
| US-20200157073-A1 | SUBSTITUTED N-ARYLETHYL-2-AMINOQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, ARG2, GOT2 | SLC6A2 2713/4885SLC6A4 3022/4885STIM1 1790/4885 |
| US-11149018-B2 | Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | AADAC, ARG2, GOT2 | SLC6A2 2713/4885SLC6A4 3022/4885STIM1 1790/4885 |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | AADAC, NAT1, EPX | SLC6A2 3264/4885SLC6A4 3468/4885STIM1 1855/4885 |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | SLC6A2 63/4885SLC6A4 84/4885STIM1 3224/4885 |
| US-20030023099-A1 | Novel fluorescent carbazole derivative | CBR3, AANAT, SIRT3 | SLC6A2 1288/4885SLC6A4 365/4885STIM1 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.